Context Therapeutics (CNTX) Share-based Compensation (2021 - 2026)
Context Therapeutics (CNTX) posted Share-based Compensation of $409220.0 for Q1 2026, down 69.21% sequentially from $1.3 million in Q4 2025, and up 39.32% YoY from $293717.0 in Q1 2025.
Context Therapeutics (CNTX) Share-based Compensation (2021 - 2026) Analysis & Trends
Context Therapeutics has reported Share-based Compensation for 6 years, with the latest figure at $409220.0 in Q1 2026.
- Quarterly Share-based Compensation rose 39.32% year-over-year to $409220.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 61.53% YoY) and the FY2025 annual result came in at $1.3 million, up 58.11% from the prior year.
- Share-based Compensation fell to $409220.0 in Q1 2026 per CNTX's latest filing, from $1.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.3 million in Q4 2025 and troughed at -$820814.0 in Q4 2023.
- A 5-year average of $172217.5 and a median of $240007.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation tumbled 481.7% in 2023, then jumped 473.25% in 2025.
- Over 5 years, Share-based Compensation stood at $215042.0 in 2022, then sank by 481.7% to -$820814.0 in 2023, then surged by 128.24% to $231821.0 in 2024, then surged by 473.25% to $1.3 million in 2025, then sank by 69.21% to $409220.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $409220.0, $1.3 million, and $2175.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | - |
| 10 | Context Therapeutics | 49.88 Mn | 49.88 Mn | - | 528,102.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 528,102.00 |
| Jun 30, 2026 | 528,102.00 |
| Mar 31, 2026 | 409,220.00 |
| Mar 31, 2026 | 409,220.00 |
| Dec 31, 2025 | 1.33 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 2,175.00 |
| Sep 30, 2025 | 2,175.00 |
| Jun 30, 2025 | -293,717.00 |
| Jun 30, 2025 | -293,717.00 |
| Mar 31, 2025 | 293,717.00 |
| Mar 31, 2025 | 293,717.00 |
| Dec 31, 2024 | 231,821.00 |
| Dec 31, 2024 | 231,821.00 |
| Sep 30, 2024 | 565,414.00 |
| Sep 30, 2024 | 565,414.00 |
| Jun 30, 2024 | -195,375.00 |
| Jun 30, 2024 | -195,375.00 |
| Mar 31, 2024 | 240,007.00 |
| Mar 31, 2024 | 240,007.00 |